Overview
Based in Antwerp, Minze Health develops clinically validated Prescription Digital Therapeutics (PDTs) for urological conditions including bladder dysfunction and incontinence, affecting hundreds of millions of patients globally. The company's solutions are used by over 160,000 patients across 20+ countries, trusted by clinicians as a complement or alternative to pharmacological treatments for lower urinary tract symptoms (LUTS).
Minze raised EUR 3.9M in December 2022 from White Fund, Capricorn Partners, and PMV. In October 2024, the company secured an additional USD 5.3M from the same core syndicate, joined by imec.istart Future Fund as a new investor, bringing total funding to approximately USD 9.2M. In September 2025, Minze entered a strategic collaboration with Apogepha (Germany) to develop a digital therapeutic specifically for male LUTS.
The urology-focused digital therapeutics category is commercially promising given aging demographics across Western Europe and the US, and growing payer and provider interest in validated behavioral and software-based interventions.
Funding history
- December 2022: EUR 3.9M from White Fund, Capricorn Partners, PMV
- October 2024: USD 5.3M from White Fund, Capricorn Digital Growth Fund, PMV, imec.istart Future Fund
Key people
In the news
- The Diary Pod in pediatric urology A newly published pediatric study compared our automated bladder diary with a conventional paper bladder diary. Across five study centers, 80 children were recruited, with almost 50 completing both formats in a randomized crossover study. 🔎 Key takeaways: • A clear family preference: 87.5% of parents and 72.9% of children preferred the Minze Diary Pod. It also scored significantly better for pleasant use, motivation, child involvement, and perceived error-free use. • Potential value for repeated
- Another important step in preparing Minze Health for scale. Data security is a top priority for our customers, and this certification shows we take it just as seriously. Great work Evelien Sommen , Sam Van Hoey and the whole R&D team!
- We’re happy to share that Minze Health has achieved ISO 27001 certification. Handling sensitive health data comes with an important responsibility. From uroflowmetry measurements to bladder diaries, patients and clinicians trust us to treat their information with care. This certification is an important confirmation of the information security processes we’ve built and strengthened across Minze, and of our ongoing commitment to protecting data as we continue to develop and scale our solutions. Thank you to the whole team and
- 600 HOMEFLOW ORDERS IN THE USA. A pretty great way to close out the week. Another milestone, and the momentum keeps building. Those next 100 orders mean 100 more opportunities to move urology diagnostics beyond the clinic and give physicians access to better real-world data. We’re proud of the progress, grateful to the practices that continue to back us, and even more excited about what comes next. 600 down. On to the next. #MinzeHealth #HomeFlow #Urology #Uroflowmetry #DigitalHealth #MedTech #RemoteMonitoring #PatientCare
- ICS 2026, here we come. Next week, our Minze team will be in Maastricht for the International Continence Society (ICS) Annual Meeting, connecting with clinicians, researchers, industry, and innovators shaping the future of continence care. First up on Wednesday, October 7 at 16:52, Lola Bladt will present results from our Lutastic+ pilot study. Her presentation, “Digital therapy for male LUTS: a pilot study demonstrating high engagement and symptom improvement,” will take place during the Male LUTS Beyond the Prostate session.
- Minze Health is heading to LSI Europe ’26 in Barcelona this week, with our CEO Tom Moore taking the stage. LSI Europe brings together leading medtech companies, investors, and strategic partners, making it a great setting to share what we’re building at Minze and where we’re heading next. Tom is always happy to connect and discuss our upcoming investment round, so if you’ll be attending and would like to learn more, feel free to reach out and find a moment to meet. Catch Tom on stage on Thursday, October 1, in the early
- Patented in the U.S. We’re proud to share that the technology behind our Diary Pod has now received U.S. patent protection. The Diary Pod takes bladder diaries beyond manual logging by automatically capturing voided volume and timing, while the app adds important context such as fluid intake, urgency, and leakages. As part of Lutastic+, the Diary Pod brings objective measurements into the therapy journey, helping patients and clinicians track progress beyond self-reported symptoms alone. A great recognition of the technology behind
- 500 HOMEFLOW ORDERS IN THE USA. A significant milestone for Minze Health — and one that deserves a moment. 500 orders means 500 opportunities to give physicians better data, better insight, and a clearer picture of their patients' health outside the clinic. It reflects the hard work of a dedicated team, physicians willing to try a different approach, and the customers and partners who believed in us along the way. To everyone who played a role in getting here — thank you. You believed in the vision, pushed through the
Alumni
Jiri VermeulenFounding CEO & Board Member
Backers
PMV (ParticipatieMaatschappij Vlaanderen)
Flemish government investment arm with a EUR 1.9B portfolio, backing tech and biotech companies with tickets up to EUR 20M.
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.